Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Pembrolizumab with Carboplatin and Paclitaxel in Early TNBC
NCT06407310Phase 2Not yet recruiting
- Sponsor
- Tel Aviv Sourasky Medical Center
- Start
- Jul 2024
- Primary completion
- Apr 2027
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
01
Overview
A Phase 2 trial of pembrolizumab in triple-negative breast cancer (TNBC), sponsored by Tel Aviv Sourasky Medical Center. Planned start Jul 2024; status: not yet recruiting.
02
Drugs
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT06407310.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06407310.